Adq. P.a 2019 Citostaticos Inyectables 5 Inc.
El Instituto Nacional del Cáncer requiere contratar el suministro de Fármacos Citostáticos Inyectables 5 de Banco de Drogas Plan Anual 2019 necesarios para el óptimo funcionamiento de los servicios clínicos.
14 oferente(s) participaron en esta licitación. El detalle de quién compitió y con qué oferta está en el registro oficial de Mercado Público.
Ver oferentes en Mercado Público →| Código | Fecha | Proveedor | Monto |
|---|---|---|---|
| 359-4088-SE19 | 30-12-2019 | Pfizer Chile S.A. | $5.236.000 |
| 359-4025-SE19 | 26-12-2019 | Fresenius Kabi Chile Limitada | $2.070.600 |
| 359-4024-SE19 | 26-12-2019 | Novartis Chile S.A. | $2.499.000 |
| 359-3824-SE19 | 09-12-2019 | Laboratorios Kampar S.A. | $456.960 |
| 359-3826-SE19 | 09-12-2019 | Pfizer Chile S.A. | $141.015 |
| 359-3732-SE19 | 09-12-2019 | Novartis Chile S.A. | $1.249.500 |
| 359-3733-SE19 | 09-12-2019 | Fresenius Kabi Chile Limitada | $1.642.200 |
| 359-3695-SE19 | 05-12-2019 | Laboratorios Kampar S.A. | $913.920 |
| 359-3661-SE19 | 28-11-2019 | Fresenius Kabi Chile Limitada | $2.320.500 |
| 359-3659-SE19 | 27-11-2019 | Novartis Chile S.A. | $3.070.200 |
| 359-3311-SE19 | 30-10-2019 | Pfizer Chile S.A. | $329.035 |
| 359-3309-SE19 | 30-10-2019 | Laboratorios Kampar S.A. | $456.960 |
| 359-3301-SE19 | 29-10-2019 | Novartis Chile S.A. | $4.641.000 |
| 359-3302-SE19 | 29-10-2019 | Fresenius Kabi Chile Limitada | $1.071.000 |
| 359-3173-SE19 | 16-10-2019 | Fresenius Kabi Chile Limitada | $2.106.300 |
| 359-3030-SE19 | 30-09-2019 | Fresenius Kabi Chile Limitada | $1.999.200 |
| 359-2654-SE19 | 02-09-2019 | Fresenius Kabi Chile Limitada | $7.318.500 |
| 359-2659-SE19 | 26-08-2019 | Laboratorios Kampar S.A. | $1.827.840 |
| 359-2653-SE19 | 26-08-2019 | Novartis Chile S.A. | $4.641.000 |
| 359-2660-SE19 | 26-08-2019 | Pfizer Chile S.A. | $329.035 |
| 359-2301-SE19 | 26-07-2019 | Novartis Chile S.A. | $16.122.299 |
| 359-2310-SE19 | 26-07-2019 | Pfizer Chile S.A. | $329.035 |
| 359-1935-SE19 | 26-06-2019 | Fresenius Kabi Chile Limitada | $1.785.000 |
| 359-1950-SE19 | 26-06-2019 | Pfizer Chile S.A. | $329.035 |
| 359-1930-SE19 | 25-06-2019 | Novartis Chile S.A. | $999.600 |
| 359-1622-SE19 | 27-05-2019 | Laboratorios Kampar S.A. | $1.827.840 |
| 359-1623-SE19 | 27-05-2019 | Pfizer Chile S.A. | $329.035 |
| 359-1601-SE19 | 24-05-2019 | Fresenius Kabi Chile Limitada | $2.856.000 |
| 359-1599-SE19 | 24-05-2019 | Novartis Chile S.A. | $2.748.900 |
| 359-1286-SE19 | 26-04-2019 | Novartis Chile S.A. | $2.748.900 |
| 359-1287-SE19 | 26-04-2019 | Fresenius Kabi Chile Limitada | $1.071.000 |
| 359-1300-SE19 | 26-04-2019 | Laboratorios Kampar S.A. | $1.827.840 |
| 359-1284-SE19 | 25-04-2019 | Industrial y Comercial Baxter de Chile Limitada | $176.797 |
| 359-1277-SE19 | 25-04-2019 | Pfizer Chile S.A. | $5.565.035 |
| 359-930-SE19 | 22-03-2019 | Pfizer Chile S.A. | $8.183.035 |
| 359-948-SE19 | 22-03-2019 | Novartis Chile S.A. | $8.486.366 |
| 359-949-SE19 | 22-03-2019 | Fresenius Kabi Chile Limitada | $6.961.500 |
| 359-962-SE19 | 22-03-2019 | Laboratorios Kampar S.A. | $1.827.840 |
| 359-550-SE19 | 28-02-2019 | Laboratorio Chile S.A. | $78.540 |
| 359-350-SE19 | 28-02-2019 | Laboratorio Chile S.A. | $78.540 |
| 359-351-SE19 | 28-02-2019 | Laboratorios Kampar S.A. | $1.827.840 |
| 359-352-SE19 | 28-02-2019 | Novartis Chile S.A. | $6.795.733 |
| 359-353-SE19 | 28-02-2019 | Pfizer Chile S.A. | $15.943.025 |
| 359-354-SE19 | 28-02-2019 | Fresenius Kabi Chile Limitada | $9.282.000 |
| 359-356-SE19 | 28-02-2019 | Laboratorio Lkm Chile SpA | $164.220 |
| 359-365-SE19 | 11-02-2019 | Fresenius Kabi Chile Limitada | $6.426.000 |
| 359-364-SE19 | 11-02-2019 | Novartis Chile S.A. | $3.213.000 |
| 359-363-SE19 | 11-02-2019 | Laboratorio Lkm Chile SpA | $492.660 |
| 359-362-SE19 | 11-02-2019 | Laboratorio Chile S.A. | $180.880 |
| 359-360-SE19 | 11-02-2019 | Pfizer Chile S.A. | $10.942.050 |
Fuente original:ficha mercadopublico.cl
